Repository logo
 

Modified Hypoxia-Inducible Factor Expression in CD8+ T Cells Increases Antitumor Efficacy

Accepted version
Peer-reviewed

Type

Article

Change log

Authors

Velica, Pedro 
Cunha, Pedro 
Vojnovic, Nikola 
Foskolou, Iosifina 

Abstract

Adoptive transfer of antitumor cytotoxic T cells is an emerging form of cancer immunotherapy. A key challenge to expanding the utility of adoptive-cell therapies is how to enhance the survival and function of the transferred T cells. Immune-cell survival requires adaptation to different microenvironments, and particularly to the hypoxic milieu of solid tumors. The hypoxia-inducible factor (HIF) transcription factors are an essential aspect of this adaptation. In this study, we undertook experiments to define structural determinants of HIF that potentiate antitumor efficacy in cytotoxic T cells. We first created retroviral vectors to deliver ectopic expression of HIF1ɑ and HIF2ɑ in mouse CD8+ T cells, together or individually, and with or without sensitivity to the oxygen-dependent HIFɑ inhibitors Von Hippel Lindau (VHL) and Factor Inhibiting HIF (FIH). HIF2ɑ, but not HIF1ɑ, drove broad transcriptional changes in CD8+ T cells, resulting in increased cytotoxic differentiation and cytolytic function against tumor targets. A specific mutation replacing the hydroxyl group–acceptor site for FIH in HIF2ɑ gave rise to the most effective antitumor T cells after adoptive transfer in vivo. In addition, co-delivering an FIH-insensitive form of HIF2ɑ with an anti-CD19 chimeric antigen receptor greatly enhanced cytolytic function of human CD8+ T cells against lymphoma cells both in vitro and in a xenograft adoptive transfer model. These experiments point to a means to increase the antitumor efficacy of therapeutic CD8+ T cells via ectopic expression of the HIF transcription factor.

Description

Keywords

Journal Title

Cancer Immunology Research

Conference Name

Journal ISSN

2326-6066

Volume Title

Publisher

American Association for Cancer Research

Publisher DOI

Publisher URL

Rights

All rights reserved
Sponsorship
Wellcome Trust (214283/Z/18/Z)